Pharmaceutical

Fulcrum and CAMP4 to develop rare blood disorder therapies

Fulcrum Therapeutics has signed a licence agreement with CAMP4 Therapeutics to develop new therapies to treat Diamond-Blackfan anaemia.

Jul 11, 2023 - 20:00
Fulcrum and CAMP4 to develop rare blood disorder therapies
Fulcrum Therapeutics has signed a licence agreement with CAMP4 Therapeutics to develop new therapies to treat Diamond-Blackfan anaemia.
Read the original article

Tags:

Previous Article

Iovance looks to advance its non-small cell lung cancer therapy

Next Article

Astellas licenses 4DMT’s AAV vector for ophthalmic targets

What's Your Reaction?

like

dislike

love

funny

angry

sad

wow

Related Posts

FDA committee recommends AstraZeneca and Sanofi’s RSV prophylactic nirsevimab

FDA committee recommends AstraZeneca and Sanofi’s RSV p...

Jun 9, 2023

Synnovation launches with $102m to advance therapy pipeline

Synnovation launches with $102m to advance therapy pipe...

Jan 25, 2024

Following board fight, Francis deSouza resigns as Illumina CEO

Following board fight, Francis deSouza resigns as Illum...

Jun 12, 2023